Showing results (111-120 of 468) with videos related to

Sort By:
Pageof 47
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast CancerGrace M Choong, Tanya L Hoskin, Judy C Boughey, et al.
Annals of Surgical Oncology|September 12, 2024
In-Breast Tumor Progression During Neoadjuvant Chemotherapy: Impact on and Factors Influencing Distant Recurrence-Free SurvivalKathryn M Eckert, Tanya L Hoskin, Carrie A Olson, et al.
SOJ Anesthesiology & Pain Management|November 4, 2015
Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 PatientsHeshan Liu, Angelina D Tan, Rui Qin, et al.
Frontiers in Oncology|March 7, 2019
Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry StudyCassia B Wang, Faisal Shahjehan, Amit Merchea, et al.
The Oncologist|September 15, 2017
Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic ExperienceBenny Johnson, Zhaohui Jin, Mark J Truty, et al.
BMC Cancer|July 15, 2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyPashtoon M Kasi, Daisuke Kotani, Michael Cecchini, et al.
Cancer Research|February 27, 2009
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cellsXianglin Wu, John R Hawse, Malayannan Subramaniam, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 12, 2015
Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into PracticeDeirdre R Pachman, Kathryn Ruddy, Lindsey R Sangaralingham, et al.
Investigational New Drugs|November 20, 2015
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignanciesJoleen M Hubbard, George Kim, Mitesh J Borad, et al.
British Journal of Cancer|November 30, 2018
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancerFotios Loupakis, Herbert I Hurwitz, Leonard Saltz, et al.
Pageof 47